BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30191737)

  • 1. Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients.
    Mohsenzadegan M; Saebi F; Yazdani M; Abolhasani M; Saemi N; Jahanbani F; Farajollahi MM
    Biomark Med; 2018 Oct; 12(10):1125-1138. PubMed ID: 30191737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer.
    Mohsenzadegan M; Shekarabi M; Madjd Z; Asgari M; Abolhasani M; Tajik N; Farajollahi MM
    Biomark Med; 2015; 9(4):391-401. PubMed ID: 25808443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis.
    Mohsenzadegan M; Madjd Z; Asgari M; Abolhasani M; Shekarabi M; Taeb J; Shariftabrizi A
    Cancer Immunol Immunother; 2013 Oct; 62(10):1609-18. PubMed ID: 23955683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-autoantibodies for discovery of prostate cancer specific biomarkers.
    Massoner P; Lueking A; Goehler H; Höpfner A; Kowald A; Kugler KG; Amersdorfer P; Horninger W; Bartsch G; Schulz-Knappe P; Klocker H
    Prostate; 2012 Mar; 72(4):427-36. PubMed ID: 22012634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
    Cereda V; Poole DJ; Palena C; Das S; Bera TK; Remondo C; Gulley JL; Arlen PM; Yokokawa J; Pastan I; Schlom J; Tsang KY
    Cancer Immunol Immunother; 2010 Jan; 59(1):63-71. PubMed ID: 19495750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
    Dai L; Li J; Ortega R; Qian W; Casiano CA; Zhang JY
    J Immunol Res; 2014; 2014():827827. PubMed ID: 24860838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
    Sreekumar A; Laxman B; Rhodes DR; Bhagavathula S; Harwood J; Giacherio D; Ghosh D; Sanda MG; Rubin MA; Chinnaiyan AM
    J Natl Cancer Inst; 2004 Jun; 96(11):834-43. PubMed ID: 15173267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.
    Leidinger P; Keller A; Milchram L; Harz C; Hart M; Werth A; Lenhof HP; Weinhäusel A; Keck B; Wullich B; Ludwig N; Meese E
    PLoS One; 2015; 10(6):e0128235. PubMed ID: 26039628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
    Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
    Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.
    Fujita K; Hayashi T; Matsuzaki K; Nakata W; Masuda M; Kawashima A; Ujike T; Nagahara A; Tsuchiya M; Kobayashi Y; Nojima S; Uemura M; Morii E; Miyoshi E; Nonomura N
    Oncotarget; 2016 Aug; 7(35):56643-56649. PubMed ID: 27494861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 19. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
    Ummanni R; Duscharla D; Barett C; Venz S; Schlomm T; Heinzer H; Walther R; Bokemeyer C; Brümmendorf TH; Murthy PV; Balabanov S
    J Proteomics; 2015 Apr; 119():218-29. PubMed ID: 25724726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.